Cytokinetics (CYTK) director Daly received 197 shares
Insider transactions reported
James M Daly (director at Cytokinetics Incorporated, CYTK) reported that they received 197 shares on Jan 15, 2026. After these transactions the filing shows 197 shares held directly.
- Reporting person
- Daly James M
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | Grant or award (A) | Common Stock1 | +197 | $63.44 | $12.5K | 197 direct |
Holdings before and after
- Common Stock: 0 to 197 direct
Footnotes from the filing
- 1. Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of Issuer's Board of Directors.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Daly report in this CYTK Form 4?
James M Daly (director at Cytokinetics Incorporated, CYTK) reported that they received 197 shares on Jan 15, 2026. After these transactions the filing shows 197 shares held directly.
How many CYTK shares does Daly hold after this filing?
The filing shows 197 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for CYTK
Across the 13 sessions after earlier CYTK headlines, the stock closed higher 9 times and lower 4 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CYTK | SPY |
|---|---|---|---|
| Jan 21, 2026 | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.2% | +1.2% |
| Jan 6, 2026 | Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference | +5.5% | +0.6% |
| Dec 22, 2025 | Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms | +4.6% | +0.6% |
| Dec 18, 2025 | Cytokinetics upgraded by Goldman with a new price target | +4.0% | +0.8% |
| Dec 17, 2025 | Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathyand 1 other headline that session | -3.5% | -1.1% |
| Dec 12, 2025 | Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy | +4.2% | -1.1% |
Earlier insider filings at CYTK
- Jan 16, 2026Director Wysenski Nancy was granted 98 shares, increasing direct ownership by 0.32% to 30,971 units (SEC Form 4)
- Jan 16, 2026Director Wierenga Wendell was granted 98 shares, increasing direct ownership by 0.30% to 32,542 units (SEC Form 4)
- Jan 16, 2026Director Kaye Edward M. Md was granted 197 shares, increasing direct ownership by 2% to 10,174 units (SEC Form 4)
- Jan 16, 2026Director Henderson John T was granted 334 shares, increasing direct ownership by 0.45% to 74,912 units (SEC Form 4)
- Jan 16, 2026Director Harrington Robert Arthur was granted 197 shares, increasing direct ownership by 1% to 18,739 units (SEC Form 4)
Keep researching CYTK
- CYTK insider tradesEvery buy and sale reported by Cytokinetics Incorporated officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- CYTK earnings historyPast Cytokinetics Incorporated earnings releases, newest first.
- CYTK financial statementsRevenue, profit, cash flow and balance sheet from Cytokinetics Incorporated's SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2004
Follow CYTK and get a push notification the moment its next story breaks.